$1.3 Billion is the total value of Casdin Capital, LLC's 38 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 18.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLFS | BIOLIFE SOLUTIONS INC | $186,594,546 | +15.5% | 8,707,165 | 0.0% | 14.30% | +19.1% | |
| RVMD | Sell | REVOLUTION MEDICINES INC | $171,030,819 | -5.5% | 4,406,875 | -21.6% | 13.11% | -2.6% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $169,613,000 | +22.6% | 1,073,500 | +0.4% | 13.00% | +26.4% |
| FLDM | Buy | STANDARD BIOTOOLS INC | $113,208,628 | -32.5% | 63,959,677 | +3.3% | 8.68% | -30.4% |
| Buy | GENEDX HOLDINGS CORP | $92,180,384 | +221.9% | 3,526,411 | +12.4% | 7.07% | +231.9% | |
| RNA | AVIDITY BIOSCIENCES INC | $85,165,755 | +60.1% | 2,084,841 | 0.0% | 6.53% | +65.1% | |
| RLAY | Buy | RELAY THERAPEUTICS INC | $55,084,702 | -10.6% | 8,448,574 | +13.8% | 4.22% | -7.8% |
| ILMN | Buy | ILLUMINA INC | $50,102,400 | +47.1% | 480,000 | +93.5% | 3.84% | +51.7% |
| NTLA | Buy | INTELLIA THERAPEUTICS INC | $44,760,000 | -13.2% | 2,000,000 | +6.7% | 3.43% | -10.5% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $41,310,000 | -22.8% | 170,000 | -52.5% | 3.17% | -20.4% |
| BPMC | BLUEPRINT MEDICINES CORP | $35,177,021 | +13.6% | 326,378 | 0.0% | 2.70% | +17.1% | |
| DNLI | DENALI THERAPEUTICS INC | $30,186,000 | +13.2% | 1,300,000 | 0.0% | 2.31% | +16.7% | |
| Sell | STRUCTURE THERAPEUTICS INCsponsored ads | $27,489,000 | -42.6% | 700,000 | -37.3% | 2.11% | -40.8% | |
| EXAS | EXACT SCIENCES CORP | $27,462,500 | -38.8% | 650,000 | 0.0% | 2.10% | -36.9% | |
| TENAYA THERAPEUTICS INC | $20,872,210 | -40.7% | 6,732,971 | 0.0% | 1.60% | -38.9% | ||
| NEUROGENE INC | $19,090,776 | -28.5% | 524,616 | 0.0% | 1.46% | -26.3% | ||
| VCYT | VERACYTE INC | $18,590,780 | -2.2% | 857,904 | 0.0% | 1.42% | +0.8% | |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $16,792,000 | -34.1% | 800,000 | 0.0% | 1.29% | -32.1% | |
| BEAM | BEAM THERAPEUTICS INC | $15,815,250 | -29.1% | 675,000 | 0.0% | 1.21% | -26.9% | |
| VERV | VERVE THERAPEUTICS INC | $14,928,379 | -63.3% | 3,059,094 | 0.0% | 1.14% | -62.1% | |
| PLRX | PLIANT THERAPEUTICS INC | $10,750,000 | -27.9% | 1,000,000 | 0.0% | 0.82% | -25.6% | |
| TANGO THERAPEUTICS INC | $10,196,034 | +8.1% | 1,188,349 | 0.0% | 0.78% | +11.6% | ||
| IPSC | CENTURY THERAPEUTICS INC | $8,176,269 | -39.0% | 3,206,380 | 0.0% | 0.63% | -37.0% | |
| 2SEVENTY BIO INC | $7,700,000 | -28.0% | 2,000,000 | 0.0% | 0.59% | -25.8% | ||
| CDXS | CODEXIS INC | $6,200,000 | -11.2% | 2,000,000 | 0.0% | 0.48% | -8.5% | |
| New | CONTINEUM THERAPEUTICS INCcl a | $5,224,288 | – | 296,666 | +100.0% | 0.40% | – | |
| Buy | KYVERNA THERAPEUTICS INC | $4,312,500 | +15.7% | 575,000 | +283.3% | 0.33% | +19.5% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $3,079,500 | -13.7% | 150,000 | 0.0% | 0.24% | -10.9% | |
| ABSCI CORPORATION | $2,997,641 | -45.8% | 973,260 | 0.0% | 0.23% | -44.0% | ||
| GH | New | GUARDANT HEALTH INC | $2,888,000 | – | 100,000 | +100.0% | 0.22% | – |
| PRIME MEDICINE INC | $1,887,280 | -26.6% | 367,175 | 0.0% | 0.14% | -24.1% | ||
| PACB | PACIFIC BIOSCIENCES CALIF IN | $1,419,127 | -63.5% | 1,035,859 | 0.0% | 0.11% | -62.3% | |
| New | GRAIL INC | $1,229,585 | – | 79,999 | +100.0% | 0.09% | – | |
| EXSCIENTIA PLCads | $1,090,890 | -10.8% | 213,900 | 0.0% | 0.08% | -7.7% | ||
| GLUE | Sell | MONTE ROSA THERAPEUTICS INC | $976,192 | -72.9% | 261,014 | -48.9% | 0.08% | -72.0% |
| GINKGO BIOWORKS HOLDINGS INC | $487,993 | -71.2% | 1,459,747 | 0.0% | 0.04% | -70.6% | ||
| New | SINGULAR GENOMICS SYSTEMS IN | $372,890 | – | 44,129 | +100.0% | 0.03% | – | |
| KRON | KRONOS BIO INC | $153,560 | -4.6% | 123,839 | 0.0% | 0.01% | 0.0% | |
| OMIC | Exit | SINGULAR GENOMICS SYSTEMS IN | $0 | – | -1,323,885 | -100.0% | -0.05% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INCcall | $0 | – | -50,000 | -100.0% | -0.10% | – |
| ABCL | Exit | ABCELLERA BIOLOGICS INC | $0 | – | -2,360,129 | -100.0% | -0.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 35 | Q2 2024 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 35 | Q2 2024 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| FATE THERAPEUTICS INC | 27 | Q4 2023 | 8.3% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| BIOLIFE SOLUTIONS INC | 25 | Q2 2024 | 14.9% |
| CODEXIS INC | 25 | Q2 2024 | 8.1% |
| SAREPTA THERAPEUTICS INC | 24 | Q2 2024 | 13.6% |
| ILLUMINA INC | 24 | Q2 2024 | 6.0% |
| DENALI THERAPEUTICS INC | 23 | Q2 2024 | 3.7% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Century Therapeutics, Inc. | April 18, 2024 | 5,190,506 | 6.1% |
| MAXCYTE, INC.Sold out | February 14, 2024 | 0 | 0.0% |
| Relay Therapeutics, Inc. | February 14, 2024 | 7,387,943 | 6.0% |
| EQRx, Inc.Sold out | November 15, 2023 | 0 | 0.0% |
| BIOLIFE SOLUTIONS INC | October 24, 2023 | 8,707,165 | 19.5% |
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-29 |
| 4 | 2024-08-26 |
| 4 | 2024-08-21 |
| 4 | 2024-08-16 |
| 13F-HR | 2024-08-14 |
| SC 13D/A | 2024-08-14 |
| 4 | 2024-08-13 |
| 4 | 2024-08-09 |
| 4 | 2024-08-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.